A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)
PHASE2CompletedINTERVENTIONAL
Enrollment
354
Participants
Timeline
Start Date
February 21, 2012
Primary Completion Date
February 26, 2013
Study Completion Date
February 26, 2013
Conditions
Herpes Zoster
Interventions
BIOLOGICAL
V212
V212 viral antigen for HZ
BIOLOGICAL
Placebo
Placebo comparator to V212 vaccine
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT01527383 - A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009) | Biotech Hunter | Biotech Hunter